Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SAB-185

Plasma-derived product · Antagonist of SARS-CoV-2 spike protein · developed by SAb Biotherapeutics

Phase 2/3 Most advanced trial (none active)
SABS Developer
2 Registered trials

What is SAB-185?

SAB-185 is a purified human immunoglobulin G preparation of polyclonal antibodies derived from the plasma of immunized transchromosomic bovines. It binds the SARS-CoV-2 spike protein, blocking viral attachment and entry into human cells, and is studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Plasma-derived product
Targets
SARS-CoV-2 spike protein
Mechanism
Antagonist of SARS-CoV-2 spike protein
Pathways
viral attachment and entry into human cells
Therapy area
Infectious disease
Developer
SAb Biotherapeutics, Inc. (SABS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
GZH7FFK82R

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04518410 Phase 2/3 Coronavirus Completed SABS
NCT04468958 Phase 1 COVID-19 Completed SABS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CoronavirusCOVID-19Covid19SARS-CoV2

More from SAb Biotherapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SABS page.

Follow SABS, the company behind SAB-185

See SABS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SABS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.